{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T15:43:56Z","timestamp":1726760636527},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Lymph&Co"},{"name":"Egbert Stichting"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.beha.2016.08.019","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T16:54:44Z","timestamp":1473440084000},"page":"161-168","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Targeting cell adhesion and homing as strategy to cure Waldenstr\u00f6m's macroglobulinemia"],"prefix":"10.1016","volume":"29","author":[{"given":"Steven T.","family":"Pals","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Spaargaren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2016.08.019_bib1","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.019_bib2","first-page":"815325","article-title":"Waldenstr\u00f6m macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models","author":"Janz","year":"2013","journal-title":"ISRN Hematol"},{"key":"10.1016\/j.beha.2016.08.019_bib3","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood.V100.4.1505.h81602001505_1505_1507","article-title":"Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events","volume":"100","author":"Sahota","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.019_bib4","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m's macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.08.019_bib5","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2012-09-454355","article-title":"MYD88 L265P in Waldenstr\u00f6m macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction","volume":"121","author":"Xu","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.019_bib6","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstom's macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.019_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.beha.2016.08.019_bib8","first-page":"3","article-title":"High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites","volume":"6","author":"Kraan","year":"2013","journal-title":"Blood Cancer J"},{"issue":"28","key":"10.1016\/j.beha.2016.08.019_bib9","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/leu.2013.348","article-title":"High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma","volume":"2014","author":"Kraan","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.08.019_bib10","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/blood-2012-12-475111","article-title":"A\u00a0mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstr\u00f6m macroglobulinemia","volume":"122","author":"Yang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.019_bib11","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1158\/0008-5472.CAN-08-3701","article-title":"Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia","volume":"69","author":"Braggio","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2016.08.019_bib12","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.clml.2013.02.006","article-title":"The bone marrow microenvironment in Waldenstr\u00f6m macroglobulinemia","volume":"13","author":"Agarwal","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.beha.2016.08.019_bib13","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2005-09-3552","article-title":"B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia","volume":"107","author":"Elsawa","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.019_bib14","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1182\/blood-2011-04-351742","article-title":"Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity","volume":"118","author":"Elsawa","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.019_bib15","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1182\/blood-2004-06-2289","article-title":"WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12","volume":"105","author":"Balabanian","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.019_bib16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3324\/haematol.10755","article-title":"Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenstrom's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance","volume":"92","author":"Martin-Jimenez","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.08.019_bib17","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1084\/jem.20050068","article-title":"Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity","volume":"201","author":"Bende","year":"2005","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.beha.2016.08.019_bib18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1084\/jem.20121801","article-title":"A\u00a0mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi","volume":"210","author":"Hoogeboom","year":"2013","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.beha.2016.08.019_bib19","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.3324\/haematol.2015.137265","article-title":"Ibrutinib and idelalisib target B cell receptor- but not CXCL12\/CXCR4-controlled integrin-mediated adhesion in Waldenstr\u00f6m macroglobulinemia","volume":"101","author":"de Rooij","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.08.019_bib20","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.cell.2004.05.014","article-title":"Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha\/beta heterodimer","volume":"117","author":"Kraus","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.beha.2016.08.019_bib21","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cell.2009.08.041","article-title":"PI3 kinase signals BCR-dependent mature B cell survival","volume":"139","author":"Srinivasan","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.beha.2016.08.019_bib22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrd3937","article-title":"Targeting pathological B cell receptor signalling in lymphoid malignancies","volume":"12","author":"Young","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.beha.2016.08.019_bib23","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.coi.2008.03.016","article-title":"Plasma cell differentiation and survival","volume":"20","author":"Tarlinton","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.beha.2016.08.019_bib24","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1111\/febs.12180","article-title":"Heparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myeloma","volume":"280","author":"Reijmers","year":"2013","journal-title":"FEBS J"},{"key":"10.1016\/j.beha.2016.08.019_bib25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/84219","article-title":"Lymphocyte traffic control by chemokines","volume":"2","author":"Moser","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.beha.2016.08.019_bib26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1034\/j.1600-065X.2003.00067.x","article-title":"Chemokines in the systemic organization of immunity","volume":"195","author":"Campbell","year":"2003","journal-title":"Immunol Rev"},{"key":"10.1016\/j.beha.2016.08.019_bib27","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1182\/blood-2007-05-075176","article-title":"Lymphoma dissemination: the other face of lymphocyte homing","volume":"110","author":"Pals","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.019_bib28","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1084\/jem.20011866","article-title":"The B cell antigen receptor controls integrin activity through Btk and PLCgamma2","volume":"198","author":"Spaargaren","year":"2003","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.beha.2016.08.019_bib29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.immuni.2006.11.012","article-title":"Bruton's tyrosine kinase and Phospholipase Cg2 mediate chemokine-controlled B cell migration and homing","volume":"26","author":"De Gorter","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.beha.2016.08.019_bib30","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","article-title":"The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia","volume":"119","author":"De Rooij","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.019_bib31","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1182\/blood-2013-02-482125","article-title":"Egress of CD19\u00a0+\u00a0CD5\u00a0+\u00a0cells into peripheral blood following treatment with the BTK inhibitor ibrutinib in mantle cell lymphoma patients","volume":"122","author":"Chang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.019_bib32","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1038\/onc.2014.181","article-title":"BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future","volume":"34","author":"Spaargaren","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.beha.2016.08.019_bib33","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1182\/blood-2014-03-564583","article-title":"C1013G\/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma","volume":"123","author":"Roccaro","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.019_bib34","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/ng1149","article-title":"Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease","volume":"34","author":"Hernandez","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.beha.2016.08.019_bib35","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1182\/blood-2012-06-436329","article-title":"MYD88 L265P mutation in Waldenstrom macroglobulinemia","volume":"121","author":"Poulain","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.019_bib36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/1476-4598-9-289","article-title":"Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells","volume":"9","author":"Hooks","year":"2010","journal-title":"Mol Cancer"},{"key":"10.1016\/j.beha.2016.08.019_bib37","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.4049\/jimmunol.152.8.3760","article-title":"Adhesion through the LFA-1 (CD11a\/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells","volume":"152","author":"Koopman","year":"1994","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.beha.2016.08.019_bib38","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1084\/jem.173.6.1297","article-title":"Adhesion of human B cells to follicular dendritic cells involves both the lymphocyte function-associated antigen 1\/intercellular adhesion molecule 1 and very late antigen 4\/vascular cell adhesion molecule 1 pathways","volume":"173","author":"Koopman","year":"1991","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.beha.2016.08.019_bib39","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1182\/blood-2007-08-106583","article-title":"The small GTPase Ral mediates SDF-1-induced migration of B cells and multiple myeloma cells","volume":"111","author":"De Gorter","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.019_bib40","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.08.019_bib41","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.08.019_bib42","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.08.019_bib43","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1182\/blood-2014-12-619163","article-title":"Ibrutinib and Idelalisib synergistically target BCR-controlled adhesion in CLL and MCL: a rationale for combination therapy","volume":"125","author":"De Rooij","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.019_bib44","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.08.019_bib45","doi-asserted-by":"crossref","first-page":"13906","DOI":"10.1073\/pnas.1409362111","article-title":"Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)","volume":"111","author":"Komarova","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.beha.2016.08.019_bib46","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.08.019_bib47","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.08.019_bib48","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","article-title":"Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-\u03b4, as therapy for previously treated indolent non-Hodgkin lymphoma","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.019_bib49","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2016.08.019_bib50","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.019_bib51","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Post-ibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T01:41:42Z","timestamp":1692495702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692616300469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1521692616300469"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2016.08.019","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting cell adhesion and homing as strategy to cure Waldenstr\u00f6m's macroglobulinemia","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2016.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}